Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Nifurtimox-d4 is intended for use as an internal standard for the quantification of nifurtimox (Item No. 21784) by GC- or LC-MS. Nifurtimox is an antiprotozoal agent.1 It is active against Taluahuén, LQ, and Brener strains of T. cruzi epimastigotes with IC50 values of 9.91, 12.28, and 10.44 µM, respectively. Nifurtimox inhibits clonogenic growth of HCT116, H838, C33A, LN18, KNS42, MDA-MB-231, and FaDu tumor cells under hypoxic conditions.2 It reduces parasitemia and increases survival in a mouse model of T. cruzi infection when administered at doses of 10 and 40 mg/kg per day.3 Dietary administration of nifurtimox (150 mg/kg per day for 28 days) increases tumor cell apoptosis and reduces tumor growth in an SMS-KCNR mouse xenograft model.4
WARNING This product is not for human or veterinary use.
1. Trypanosoma cruzi: Effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem. Pharmacol. 65(6), 999-1006 (2003).
2. The anti-
3. Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis. Mem. Inst. Oswaldo Cruz 112(9), 596-608 (2017).
4. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J. Pediatr. Hematol. Oncol. 31(3), 187-193 (2009).